Angiogenex Inc (AGGX) 0.2000 $AGGX
Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 6.96 (-0.04), QLTI: 1.54 (-0.01), FOMX: 6.90 (-0.19), AAVL: 4.14 (-0.18), REGN: 381.08 (-7.89)
Global Breast Cancer Pipeline Review 2015
M2 - Tue Nov 03, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/3xkrvl/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Breast Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Breast Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Breast Cancer - Pipeline Products under Development by Companies 5 Breast Cancer Companies and Product Overview 6 Breast Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abcodia Ltd. - Abviva, Inc. - Accelerated Medical Diagnostics - Acobiom - Advanced Cell Diagnostics, Inc. - Affichem SA - AIT Austrian Institute of Technology GmbH - Almac Diagnostics Limited - Amarantus Bioscience Holdings, Inc. - AngioGenex, Inc. - Armune BioScience, Inc. - Arno Therapeutics, Inc. - AroCell AB - ArtemixRx - Ascendant Diagnostics, LLC - Assurance Biosciences, Inc. - Atossa Genetics, Inc. - Autoimmune Technologies, LLC - Ayanda Biosystems S.A. - Becton, Dickinson and Company - Bio Gene Ltd. - BioAffinity Technologies, Inc. - Biocrates Life Sciences AG - Biodesix Inc. - BioMarCare Technologies Ltd. - BioMark Diagnostics Inc. - BioMark Technologies Inc. - BioMarker Strategies, LLC - bioMerieux S.A. - Biosceptre (Aust) Pty Ltd - BioSystems International - bioTheranostics, Inc. - Boston College For more information visit http://www.researchandmarkets.com/research/3x...ast_cancer
ATOS: 0.32 (-0.03)
Metastatic Breast Cancer - Pipeline Review, H1 2015 - Reviews Key Pipeline Products Under Drug Profile Section
M2 - Fri Aug 14, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kdtzh/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Key Topics Covered: - Introduction - Metastatic Breast Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - AbbVie Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Amarna Therapeutics B.V. - Amgen Inc. - AngioGenex, Inc. - Aphios Corporation - arGEN-X BV - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Bayer AG - BIOCAD - Biocon Limited - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CASI Pharmaceuticals Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Dompe Farmaceutici S.p.A. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/2k...tic_breast
ADXS: 8.82 (-0.19), BMRN: 82.94 (-1.16), CLDX: 4.32 (-0.40), AMGN: 156.78 (-1.22), LLY: 74.43 (-0.48), CASI: 1.39 (+0.07), BMY: 72.73 (-0.68), AZN: 28.96 (-0.68), AVEO: 1.06 (-0.01), ABBV: 60.75 (-0.98), CORT: 5.47 (-0.17), CELGZ: 1.46 (-0.04)
Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 6.96 (-0.04), QLTI: 1.54 (-0.01), FOMX: 6.90 (-0.19), AAVL: 4.14 (-0.18), REGN: 381.08 (-7.89)
Global Breast Cancer Pipeline Review 2015
M2 - Tue Nov 03, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/3xkrvl/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Breast Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Breast Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Breast Cancer - Pipeline Products under Development by Companies 5 Breast Cancer Companies and Product Overview 6 Breast Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abcodia Ltd. - Abviva, Inc. - Accelerated Medical Diagnostics - Acobiom - Advanced Cell Diagnostics, Inc. - Affichem SA - AIT Austrian Institute of Technology GmbH - Almac Diagnostics Limited - Amarantus Bioscience Holdings, Inc. - AngioGenex, Inc. - Armune BioScience, Inc. - Arno Therapeutics, Inc. - AroCell AB - ArtemixRx - Ascendant Diagnostics, LLC - Assurance Biosciences, Inc. - Atossa Genetics, Inc. - Autoimmune Technologies, LLC - Ayanda Biosystems S.A. - Becton, Dickinson and Company - Bio Gene Ltd. - BioAffinity Technologies, Inc. - Biocrates Life Sciences AG - Biodesix Inc. - BioMarCare Technologies Ltd. - BioMark Diagnostics Inc. - BioMark Technologies Inc. - BioMarker Strategies, LLC - bioMerieux S.A. - Biosceptre (Aust) Pty Ltd - BioSystems International - bioTheranostics, Inc. - Boston College For more information visit http://www.researchandmarkets.com/research/3x...ast_cancer
ATOS: 0.32 (-0.03)
Metastatic Breast Cancer - Pipeline Review, H1 2015 - Reviews Key Pipeline Products Under Drug Profile Section
M2 - Fri Aug 14, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kdtzh/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Key Topics Covered: - Introduction - Metastatic Breast Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - AbbVie Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Amarna Therapeutics B.V. - Amgen Inc. - AngioGenex, Inc. - Aphios Corporation - arGEN-X BV - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Bayer AG - BIOCAD - Biocon Limited - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CASI Pharmaceuticals Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Dompe Farmaceutici S.p.A. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/2k...tic_breast
ADXS: 8.82 (-0.19), BMRN: 82.94 (-1.16), CLDX: 4.32 (-0.40), AMGN: 156.78 (-1.22), LLY: 74.43 (-0.48), CASI: 1.39 (+0.07), BMY: 72.73 (-0.68), AZN: 28.96 (-0.68), AVEO: 1.06 (-0.01), ABBV: 60.75 (-0.98), CORT: 5.47 (-0.17), CELGZ: 1.46 (-0.04)
